Corcept Therapeutics Incorporated (CORT)
NASDAQ: CORT · Real-Time Price · USD
75.51
-0.24 (-0.32%)
At close: Nov 14, 2025, 4:00 PM EST
75.54
+0.03 (0.04%)
After-hours: Nov 14, 2025, 4:20 PM EST
Corcept Therapeutics Revenue
Corcept Therapeutics had revenue of $207.64M in the quarter ending September 30, 2025, with 13.75% growth. This brings the company's revenue in the last twelve months to $741.17M, up 17.92% year-over-year. In the year 2024, Corcept Therapeutics had annual revenue of $675.04M with 39.94% growth.
Revenue (ttm)
$741.17M
Revenue Growth
+17.92%
P/S Ratio
10.58
Revenue / Employee
$1,482,344
Employees
500
Market Cap
7.95B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 675.04M | 192.67M | 39.94% |
| Dec 31, 2023 | 482.38M | 80.52M | 20.04% |
| Dec 31, 2022 | 401.86M | 35.88M | 9.80% |
| Dec 31, 2021 | 365.98M | 12.10M | 3.42% |
| Dec 31, 2020 | 353.87M | 47.39M | 15.46% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
CORT News
- 11 days ago - Corcept Therapeutics Incorporated (CORT) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 11 days ago - Corcept Therapeutics Announces Third Quarter Financial Results, Oncology Development Programs and Provides Corporate Update - Business Wire
- 18 days ago - Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call - Business Wire
- 4 weeks ago - Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment - Business Wire
- 4 weeks ago - Corcept Transition To New Specialty Pharmacy Well Underway - Seeking Alpha
- 4 weeks ago - Corcept Submits Marketing Authorization Application to European Medicines Agency for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer - Business Wire
- 6 weeks ago - Curant Rare Announces Pharmacy Partnership with Corcept Therapeutics - Business Wire
- 6 weeks ago - 4 Biotechnology Stocks That Outshine In Momentum Amid Strong Technicals - Benzinga